Rockville, MD -- (SBWire) -- 02/16/2019 --Implantable Pump Catheter Market: Overview
Implantable pump catheter is expected to witness high demand on the backdrop of increased prevalence of pulmonary arterial hypertension (PAH). Implantable pump catheter facilitates catheter implantation during treatment of PAH-affected patients and automates the administration of doses, and have emerged as a boon for patients with PAH as they have witnessed significant improvement in quality of life post-treatment.
Significant reduction in the rate of blood stream infections (BSIs) as site infections, in contrary to that with apropos of external IV systems, is a key benefit of implantable pump catheter which is increasing its palpability in PAH treatment. Implantable pump catheter also aids in eliminating chronic treprostinil-induced, SC administration-associated infusion site pain, which in turn has driven its demand among hospitals and ambulatory surgical centers (ASCs).
The U.S. Food and Drug Administration has recently approved the SynchroMed II myPTM Personal Therapy Manager, an implantable pump catheter device that offers patient-managed pain control. This implantable pump catheter provides patients with various chronic pain that include diabetes, cancer and heart disease, for managing unpredictable pain via delivering on-demand dosages within confines set by their provider.
Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=861
Key players in the implantable pump catheter market are encouraged to innovate and enhance accessibility to care for patients in tandem with the upward spiral of the opioid crisis. Advancements in implantable pump catheter are being deemed essential by healthcare professionals, as they hold immense potential to offset the requirement for oral opioids that are associated with significant risks to PAH-affected patients. Ability of direct management of medical condition from smartphone applications is a ground breaking innovation that is gaining palpability in the implantable pump catheter market.
A typical infusion system consists of two implanted components: a pump and a catheter. Catheter is a thin, flexible tube that connects to implantable pump through catheter port. The catheter is made of radiopaque silicone with enhanced radiopacity at the distal tip. Whereas, the pump delivers medication through the catheter to a specific site in body where it can have the best effect. An implantable pump comprises housing, a drug reservoir, a metering device, and a catheter access port. The catheter access port is guarded by a denial device which is configured to prevent insertion of a needle into the catheter access port. Whereas, the drug reservoir is coupled to the housing and has a reservoir outlet. This reservoir outlet is coupled to a metering device that has its own metered outlet. The catheter access port is fluidly coupled to the metered outlet and is configured for receiving a needle to infuse drug directly into a catheter.
The implantable pump catheter and the suture less connector are part of the Medtronic Implantable System for Remodulin that store and deliver Remodulin (treprostinil) injection into the bloodstream. The catheter connects to the pump catheter port. The pump is anchored in the pump pocket using the suture loops located on the outside of the pump.
Implantable Pump Catheter Market: Drivers and Restraints
Primary factors driving implantable pump catheter market include growing need for safe and effective guiding technology for PAH. Besides, rising prevalence of pulmonary arterial hypertension disease, increasing adoption of Remodulin for pulmonary arterial hypertension treatment, increase in healthcare spending, and rise in awareness, creating high potential growth opportunities for upcoming players of implantable pump and catheter. However, unawareness towards the procedure, high cost of treatment and device, and lack of reimbursement in some under developing countries are the factor limiting the growth of the global implantable pump catheter market.
Besides, possible system complications such as tissue damage or a loss of or change in therapy, might lead to a return of underlying symptoms, drug withdrawal symptoms, serious injury, or death and might require surgery to replace or remove the pump, catheter, or catheter fragment. The pump, catheter, or catheter fragment could migrate within the body or erode through the skin. Moreover, there could be undesirable changes in therapy, possibly related to cellular changes around the tip of the catheter. Apart from this, the catheter could leak, tear, or become disconnected, resulting in delivery of medication into the area under the skin where the pump is implanted or along the catheter path. Also, the catheter could kink or become blocked resulting in no delivery of medication.
Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=861
Implantable Pump Catheter Market: Overview
The global market for echogenic catheters is highly consolidated, and dominated by only one player in the global space. Medtronic is the only player currently offering implantable pump catheter for Remodulin for the patient suffering from pulmonary arterial hypertension. This device has been granted on December 22, 2017, after eight years of study, by the FDA. The authority granted pre-market approval (PMA) to the fully implantable system for Remodulin. This groundbreaking pump and catheter system allows patients to benefit from Remodulin while minimizing the inconvenience and risks associated with having an external intravenous catheter.
Implantable Pump Catheter Market: Regional Wise Outlook
Geographically, the global implantable pump catheter market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe is expected to be the leader in global implantable pump catheter market owing to concentration of key market players, and early adoption in the region. The market in Asia Pacific excluding Japan, China and MEA are expected to show sluggish growth during the forecast period. However, Japan is expected to show high growth owing to their high per person healthcare spending.
Implantable Pump Catheter Market: Key Players
Medtronic is the only player operating in this market. Examples of some of the major players in the global implantable pump catheter market are Medtronic, etc. Medtronic offers implantable pump along with catheter.
For more information on this report, please visit:https://www.factmr.com/report/861/implantable-pump-catheter-market
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Implantable Pump Catheter Market Research and Forecast 2018